within Pharmacolibrary.Drugs.ATC.L;

model L01AD01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 3.3333333333333335,
    adminDuration  = 600,
    adminMass      = 0.2,
    adminCount     = 1,
    Vd             = 0.03,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Carmustine (BCNU) is a nitrosourea alkylating agent used as an antineoplastic (anticancer) drug, mainly for the treatment of brain tumors, multiple myeloma, and lymphomas. It is cytotoxic and works by cross-linking DNA and RNA, thereby inhibiting DNA replication and transcription. Carmustine is approved and still used clinically, particularly for brain tumors due to its ability to cross the blood-brain barrier.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult cancer patients, typical dosing regimen; parameters for intravenous administration.</p><h4>References</h4><ol><li>Alison B Fleming, W Mark Saltzman,Pharmacokinetics of the carmustine implant.,Clinical pharmacokinetics,2002<a href='https://pubmed.ncbi.nlm.nih.gov/12074689/'>https://pubmed.ncbi.nlm.nih.gov/12074689/</a></li><li>Neal Shah, Afroz S Mohammad, Pushkar Saralkar, Samuel A Sprowls, Schuyler D Vickers, Devin John, Rachel M Tallman, Brandon P Lucke-Wold, Katherine E Jarrell, Mark Pinti, Richard L Nolan, Paul R Lockman,Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatment of breast cancer brain metastases.,Pharmacological research,2018<a href='https://pubmed.ncbi.nlm.nih.gov/29604436/'>https://pubmed.ncbi.nlm.nih.gov/29604436/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01AD01;
